AC
AEGR

Ascend Capital’s Aegerion Pharmaceuticals AEGR Stock Holding History

Ascend Capital’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-124,800
Closed -$2.37M – 184
2015
Q2 		$2.37M Buy
+124,800
New +$2.7M 0.08% 126

Other funds holding AEGR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ascend Capital's AEGR Position: Q3 2015 in Review

Ascend Capital sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2015, closing a stake of 124,800 shares — an estimated $2.37M sold.

Ascend Capital first reported a position in AEGR in Q2 2015 and held it in 1 quarter. The position peaked at $2.37M in Q2 2015. 96 funds tracked by Wall St. Rank hold AEGR as of Q3 2015.

  • Ascend Capital reported no remaining Aegerion Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Ascend Capital sold 124,800 Aegerion Pharmaceuticals shares in Q3 2015, an estimated $2.37M.
  • Ascend Capital first reported a position in Aegerion Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Ascend Capital's Aegerion Pharmaceuticals position peaked at $2.37M in Q2 2015.
  • 96 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2015.

Based on Ascend Capital's 13F filing for Q3 2015, filed 13 Nov 2015.